16206-19-2 Usage
Uses
Used in Pharmaceutical Industry:
[1,2,5]oxadiazolo[3,4-d]pyrimidine-5,7-diamine 1-oxide is used as a potential bioactive agent for its possible therapeutic effects. [1,2,5]oxadiazolo[3,4-d]pyrimidine-5,7-diamine 1-oxide's unique structure, which includes an oxadiazole ring and a pyrimidine ring with a 1-oxide functional group, may contribute to its effectiveness in various medicinal applications.
Used in Drug Design:
[1,2,5]oxadiazolo[3,4-d]pyrimidine-5,7-diamine 1-oxide is used as a compound in drug design due to its potential to be developed into new pharmaceuticals. Its structure may allow for the creation of novel drugs with specific therapeutic properties, pending further research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 16206-19-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,2,0 and 6 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 16206-19:
(7*1)+(6*6)+(5*2)+(4*0)+(3*6)+(2*1)+(1*9)=82
82 % 10 = 2
So 16206-19-2 is a valid CAS Registry Number.
16206-19-2Relevant academic research and scientific papers
Facile synthesis and NO-generating property of 4H-[1, 2, 5]oxadiazolo[3, 4-d]pyrimidine-5, 7-dione 1-oxides
Sako, Magoichi,Souichi Oda, Seiji Ohara,Hirota, Kosaku,Maki, Yoshifumi
, p. 6947 - 6951 (2007/10/03)
4H-[1, 2, 5]Oxadiazolo[3, 4-d]pyrimidine-5, 7-dione 1-oxides (2) are conveniently prepared in high yields by the oxidative intramolecular cyclization of 6-amino-5-mtro-lH-pyrimidine-2, 4-diones (1) employing iodosylbenzene diacetate as an oxidant in the presence of lithium hydride. The generation of nitric oxide (NO) and NO-related species from 2 occurs in the presence of thiols such as AT-acetylcysteamine, cysteine, and glutathione under physiological conditions. The evidence for the NO generation derives from mechanistic interpretations for the reaction of 2 with thiols and other chemical observations.
